The disclosure provides new medical device and manufacturing methods as well as chemicals that enhance delivery of pharmaceuticals from a transdermal patch, where the patch may include a film, adhesive, emulsifier, tackifier, or hydrogel.

Compositions, devices, and methods for transdermal administration of olanzapine and uses thereof, e.g., to treat nausea and vomiting.

A wearable patch for the transdermal delivery of cannabidiol (CBD). Cannabidiol is delivered in in the form of a CBD mixture which comprises CBD oil loaded into liposomes. The CBD mixture can be delivered without the use of dermal enhancers. A transdermal patch is preloaded with the CBD mixture and placed upon the skin to penetrate the dermis layer, where the CBD mixture will diffuse into the interstitial body fluid. The patch comprises microneedles and the CBD mixture which is preloaded into or on the needles depending on the type of microneedles used.

The present disclosure relates to the transdermal administration of cannabidiol (CBD) for the reduction of seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE).

Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

Advantageously, para-chloroaniline (PCA) is minimal in antimicrobial articles prepared according to the method of the invention. A method of forming an antimicrobial article according to the invention comprises steps of: providing a polymerizable composition; incorporating an antimicrobially effective amount of at least one chlorhexidine-containing antimicrobial agent into the polymerizable composition; and, polymerizing the polymerizable composition to form chlorhexidine-containing polymer of the antimicrobial article, wherein processing temperature during the method is less than about 80° C.

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising an asenapine-containing layer structure, said asenapine-containing layer structure comprising A) a backing layer and B) an asenapine-containing layer, wherein the transdermal therapeutic system comprises a silicone acrylic hybrid polymer.

The present invention provides a patch comprising a backing, and an adhesive layer on the backing, wherein the adhesive layer contains at least one drug selected from the group consisting of oxybutynin and a pharmaceutically acceptable salt thereof, a pressure-sensitive adhesive base, and diflucortolone valerate, and the content of the diflucortolone valerate is 0.0007 to 0.05% by mass based on the total mass of the adhesive layer.

Provided is a transdermal drug delivery system comprising cannabidiol, or a cannabidiol salt alone or in combinations thereof. Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and/or prevention of pain and/or inflammation.

A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.